Posted on 16/08/2010 in Pharmaceutical Company Product News Bristol-Myers Squibb is attending a medical conference this week to present new clinical data on a treatment for use among kidney transplant patients.
A total of seven presentations will be given by the company at the International Congress of the Transplantation Society in Vancouver on the subject of belatacept, an investigational selective T cell co-stimulation blocker.
These presentations include data from a phase III study and are designed to highlight the advantages of the treatment among adult kidney transplant patients, compared to alternatives such as cyclosporine.
Dr Brian Daniels, senior vice-president of global development and medical affairs at Bristol-Myers Squibb, said: "We are committed to the development of this compound as a potential therapeutic option for kidney transplant patients."
The treatment is currently under review for approval by the European Medicines Agency and the US Food and Drug Administration, among other global regulators.
Last week, Bristol-Myers Squibb announced its renewed commitment to supporting a range of Aids drug assistance programmes being conducted in the US, agreeing to continue supplying drugs such as Reyataz and Sustiva. Other news stories from 16/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
